AIM ImmunoTech

Thomas K.

Equels remains CEO, visible through frequent communications and a ‘CEO Corner.’ While the team executed on DURIPANC enrollment and NYSE American compliance was regained in June 2026, the long history of development without approvals, persistent going‑concern warnings, heavy dilution and dependence on promotional financing detract from perceived execution quality.

Governance shows standard SEC compliance, but shareholder alignment is questionable given repeated capital raises.